Caplin Point Labs Q2 FY27 Earnings Call: Reaffirms 20-25% US Growth, Q2 Dip Called Aberration (CAPLIPOINT)

Strong H1 Margins, Q2 Flagged as an Aberration

• H1 EBITDA margin of 34.2% — up from 29.5% in H1 FY 2025-2026; H1 PBT margin rose to 25.5% from 19.9%, a 5% to 5.5% improvement (CFO D. Muralidharan).
• Other expenses rose 18% QoQ and 13% YoY in Q2 FY 2026-2027 — driven primarily by freight; management cited a global air/sea freight environment that was "not very conducive" over the last 3-4 months, plus seasonal August-October increases tied to the US/Latin America holiday season.
• Freight offset via pricing — CFO D. Muralidharan said higher freight was compensated through pricing (FOB or PAS basis dispatches), lifting contribution margin by 1.5% QoQ, while PBT, EBITDA and PAT remained flat sequentially in Q2 FY 2026-2027 vs Q1 FY 2026-2027.
• Q2 FY 2026-2027 called an aberration — the CFO said various factors will get moderated and the company will be "back on rails" compared to FY 2025-2026's percentage levels — or better them — between Q3 and Q4 FY 2026-2027.
• No forex hedging program — the company relies on a natural hedge, with roughly 30% of goods imported from China and paid for in USD; no quantified FX impact for H1 FY 2026-2027 was disclosed.
• Raw material inflation unquantified — Chairman CC Parthiban declined to quantify, saying prices will continue to rise amid geopolitical risk, wars and tariff wars, factors beyond the company's control.

US Growth Target Reaffirmed; PBT Dip Attributed to Timing

• 20-25% US revenue growth target for FY 2026-2027 reaffirmed — Vice Chairman Vivek Parthiban said the company "should be on target," responding to an analyst who cited an earlier 25-30% FY27 target and the planned production line upgradation slowing H2 FY 2026-2027.
• US PBT halved from Rs.33 crores to Rs.16 crores — (comparison period not specified on the call); Vivek Parthiban said it is "probably more of a timing than anything else" and "not really a correct metric to discuss on a quarter-to-quarter basis"; no specific long-run US margin target was quantified.
• Q1 B2B milestone revenue did not repeat — management explained a relatively large B2B milestone revenue accrual in Q1 FY 2026-2027 did not repeat in Q2 FY 2026-2027, characterizing the PBT margin dip as a timing issue rather than US market stress.
• 40 products launched in the US to date — as of Q2 FY 2026-2027, with the regulatory pipeline and presence in Canada and UAE continuing to expand; the next 12 months flagged as a focus period for inventory and market share to avoid launching into immediate backorders.
• CSU daily average sales nearly doubled — from ~$33,000 in FY 2025-2026 to ~$61,000 currently (H1 FY 2026-2027); H1 FY 2026-2027 sales have already surpassed full-year FY 2025-2026 sales; management expects CSU to double revenue and profitability in FY 2026-2027.
• Caplin Steriles growing ~24-25% in FY 2026-2027 — now almost a Rs.500 crore company; management cautioned against QoQ comparisons, saying YoY growth remains healthy though still not in line with Caplin Point's longer-term rate.
• Self-imposed slowdown from line upgrades — lines 1 and 3 at Caplin Steriles are being upgraded, with downtime in Q2 FY 2026-2027 and Q3 FY 2026-2027 (until December) and catch-up expected from Q4 FY 2026-2027 onwards; management said there is no dearth of orders.

Mexico Entry, Distribution Acquisition and the Asset-Light China Play

• LATAM is ~68% of revenues (FY 2026-2027) — an analyst noted growth has softened versus the blended rate and asked whether LATAM can return to 18-20% growth; management gave no numeric LATAM growth target, pointing instead to the Mexico factory plan and complementary businesses.
• Mexico distribution acquisition in due diligence — the Chairman's visit in January 2027 (Q4 FY 2026-2027) will complete the acquisition; management is evaluating a deal that gives a "jump start" into Mexico distribution, consistent with its LATAM model of "a distribution concept with a strong supply chain back end."
• Mexico factory targeted in ~2-3 years — CC Parthiban (relocating to LATAM in January 2027) said the plant will make liquid orals and IV fluids, with output exported in the company's own trucks to Central America; the Guatemala City distribution model will be replicated, stocking 50-60 products in own warehouses across 6-7 Central American countries.
• Private-market focus in larger LATAM markets — in Mexico, Brazil, Chile and Colombia the model targets small chains, wholesalers and individual pharmacies to eliminate intermediaries and go directly from manufacturing to the last mile.
• China asset-light phase two — management cited the Chinese government's introduction of VBP (volume-based purchase), which "resulted in price erosion for local Chinese companies," as creating an opportunity to source raw materials and products from China for larger Latin American geographies; drug substances will be imported from China to India for biosimilar fill-finish at the COL facility.
• 2030 outlook — CC Parthiban said by 2030, with facilities completed, registrations obtained and commercial operations running, he is "very confident" of increasing profits and cash flow by 2030, but gave no numeric target.

COL2 Timeline Slips Again; Injectables and API Build-Out

• COL2 completion guided by August FY 2027-2028 — Vivek Parthiban said Caplin Point is "likely to complete the project by August of next year," responding to an analyst's flag that the deadline has repeatedly shifted from December 2026 to March 2027 to August 2027.
• First meaningful COL2 revenue in FY28, FY29 and beyond — the full cycle of site transfer, stability runs, product filing and triggering an inspection takes 15-18 months from facility completion; aseptic products will be made through isolator technology, which management stated is the latest expectation as per FDA and EU Annex 1 guidelines.
• COL2 to initially house 6 injectable lines — including ophthalmic and blow-fill seal lines, with provision for further expansion; management is confident it will be among the best state-of-the-art sterile facilities in India.
• FY28 US launch pipeline trimmed from 14+ to 10 — management rationalized filings based on market dynamism, noting products with 2-3 players at the development stage can face 7-8 by launch, prioritizing product excellence over launch counts.
• Pre-filled syringe progress — exhibit batches completed for 2 products with 12 more under development; an additional 10 products planned for US launch in FY 2027-2028.
• 5 APIs scaled up — 4 as secondary source to existing approved products, 1 as primary source; first DMF filings from the site expected within FY 2027-2028; oncology API site to come up before end of CY 2027.
• CRO capacity expanding from 72 beds to 120 beds by end of FY 2026-2027 — expected to enable ~6-8 BE studies per month from FY 2027-2028, driven by internal oncology, soft gel and OSD pipeline products completing pivotal studies.

Inspection Classification Pending; Paperless Factory Near

• USFDA inspection classification pending — for the Tumdi Pundi facility inspected in August 2026, management has responded comprehensively including monthly updates; clarity possible "over the next few weeks"; management characterized the situation as "status quo" and did not specifically confirm whether pending approvals or planned US launches are on hold.
• 7-point "institutional intelligence" framework — automation, digitized architecture, video SOPs, CCTV 24x7, biometrics, a quality oversight team, and Edge AI-enabled cameras (work in progress) across the factories.
• Fully paperless factory in 2-3 months — shop-floor digitization is well advanced (QC and micro areas already linked); digitization and video SOPs complete by Q4 FY 2026-2027, ensuring data-integrity/audit-trail readiness for USFDA and other auditors.
• New machinery imported from Germany, Italy and USA — installation at CSL and COL facilities likely completed in 1.5-2 years from the call (by FY 2028-2029); retrofitting of lines installed over the last 10-15 years has constrained production ramp-up.
• Three India factories under construction — likely completed in 2-2.5 years (by FY 2029-2030); management sees a "huge opportunity" in the US in 2-2.5 years (~FY 2028-2029).

Margin Guidance, Cash Deployment and Delayed Gratification

• Margins to be maintained over the next 1.5 years — CC Parthiban said current margin levels will be maintained through ~FY 2027-2028, while "the best will happen starting from 2030"; he declined to over-promise interim upside given registration, BE-study and competitive complexities.
• EBITDA margins to hold — management said EBITDA margins seen in FY 2026-2027 should be very similar going forward.
• ~Rs.1,500 crores of free cash on the books — analyst Abhijay (AJ Capital) estimated ~Rs.300 crores could go toward the Mexico distribution acquisition and 12-plus oncology ANDAs over the next 12-18 months; Vivek Parthiban said it is "a little too early" to project return on capital — both transactions are under evaluation/due diligence, with no spend or return commitment quantified.
• 12-plus oncology ANDAs under evaluation — filed and approved products in the US, intended as a kickstart versus building from scratch; management intends to pay less than the cost of developing them in-house (due diligence ongoing).
• No buyback commitment — CC Parthiban said an "extraordinary and meaningful" acquisition could deploy the cash but timing "is not in our hands" (anywhere from 6 months to 2+ years away); he preferred retaining liquidity, asking shareholders to wait 2-3 years for the payoff.
• ROE of 20% plus in FY 2026-2027 — CFO D. Muralidharan said this is above the industry average despite ongoing investment; each new facility takes 3 to 4 years to meaningfully add to ROE.
• Two-year growth confidence — CC Parthiban said the company is "very sure" it will grow "at a very healthy clip" over the next two years (i.e., through FY 2028-2029); execution is without any bank debt ("living within our means").